SCYNEXIS Inc SCYX

Healthcare Biotechnology

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

NDAQ:SCYX - Post by User

SCYNEXIS Inc > Stop Raising Dilutive Funds

<< Previous

Bullboard Posts

Next >>

Comment by dmacdon Jan 21, 2022 3:35pm

124 Views

Post# 34344387

RE:RE:RE:RE:RE:Stop Raising Dilutive Funds

Valued at cash again... well plus the long term debt. Expecting $20M burn as sales will take a while. Question is can they avoid another dilution with profits within next 3 or 4 quarters. The new prescription rebilling code was late in quarter and will take a quarter to kick in. Will buy more if the gap looks to be closing, otherwise no more for me. Mario has diluted so much that one wonders if there was a better way to get there for the shareholder.

<< Previous

Bullboard Posts

Next >>

BlackBerry: 600,000 cyberattacks on critical infrastructure in Q3 2024